Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: Toward an integrative inflammatory hypothesis of schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 2, 2014, Pages 376-387

  García Bueno, Borja ^a   Bioque, Miquel ^b   Mac Dowell, Karina S ^a   Barcones, M Fe ^c   Martínez Cengotitabengoa, Monica ^d   Pina Camacho, Laura ^e   Rodríguez Jiménez, Roberto ^a   Sáiz, Pilar A ^f   Castro, Carmen ^g   Lafuente, Amalia ^h   Santabárbara, Javier ^c,i   González Pinto, Ana ^d   Parellada, Mara ^e   Rubio, Gabriel ^a   García Portilla, M Paz ^f   Micó, Juan A ^g   Bernardo, Miguel ^b   Leza, Juan C ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL TXAGORRITXU   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSITY OF OVIEDO   (Spain)

^g UNIVERSITY OF CÁDIZ   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

biomarker; first episode psychosis; inflammatory balance; schizophrenia

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ARIPIPRAZOLE; CLOZAPINE; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; OLANZAPINE; PALIPERIDONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN J2; PROSTAGLANDIN SYNTHASE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; 15-DEOXYPROSTAGLANDIN J2; BIOLOGICAL MARKER; PROSTAGLANDIN D2;

ADULT; AGE DISTRIBUTION; AMINO ACID BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; CASE CONTROL STUDY; CELLS; CONTROLLED STUDY; DSM-IV; FEMALE; GENDER; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RACE; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; CELLULAR IMMUNITY; COMPLICATION; IMMUNOLOGY; INFLAMMATION; PHENOTYPE; PSYCHOTIC DISORDERS; TIME;

ADOLESCENT; ADULT; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; MALE; PHENOTYPE; PROSTAGLANDIN D2; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; TIME FACTORS; YOUNG ADULT;

EID: 84895756733     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt001     Document Type: Article

References (60)

1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635-645.
2. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19-28.
3. Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med. 2006;12: 1016-1022.
4. Insel TR. Rethinking schizophrenia. Nature. 2010;468: 187-193.
5. Kuehn BM. FDA: Gene tests need premarket approval. JAMA. 2010;304:145.
6. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res. 2009;110:1-23.
7. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol. 2006;147 Suppl 1:S232-S240.
8. Müller N, Schwarz MJ. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci. 2008;258 Suppl 2:97-106.
9. Shi J, Levinson DF, Duan J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460:753-757.
10. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-Analysis. J Clin Psychiatry. 2012;73: 414-419.
11. Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 2011;132:96-110.
12. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry. 2000;5:150-158.
13. Maes M, Bosmans E, Ranjan R, et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res. 1996;21:39-50.
14. Sugino H, Futamura T, Mitsumoto Y, Maeda K, Marunaka Y. Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide- treated mice. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:303-307.
15. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29:141-152.
16. Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res. 2000;34:369-382.
17. Kaiya H, Uematsu M, Ofuji M, et al. Elevated plasma prostaglandin E2 levels in schizophrenia. J Neural Transm. 1989;77:39-46.
18. Das I, Khan NS. Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects. Prostaglandins Leukot Essent Fatty Acids. 1998;58:165-168.
19. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151-157.
20. van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)- [11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820-822.
21. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry. 2007;7:46.
22. Drexhage RC, van der Heul-Nieuwenhuijsen L, Padmos RC, et al. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int J Neuropsychopharmacol. 2010;13:1369-1381.
23. García-Bueno B, Caso JR, Leza JC. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neurosci Biobehav Rev. 2008;32:1136-1151.
24. Martínez-Gras I, Pérez-Nievas BG, García-Bueno B, et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res. 2011;128:15-22.
25. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA. 2003;100:1920-1925.
26. Madrigal JL, Hurtado O, Moro MA, et al. The increase in TNF-Alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology. 2002;26:155-163.
27. Middleton G, Hamanoue M, Enokido Y, et al. Cytokineinduced nuclear factor kappa B activation promotes the survival of developing neurons. J Cell Biol. 2000;148:325-332.
28. Galea E, Heneka MT, Dello Russo C, Feinstein DL. Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol. 2003;23:625-635.
29. Kapadia R, Yi JH, Vemuganti R. Mechanisms of antiinflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13:1813-1826.
30. García-Bueno B, Madrigal JL, Lizasoain I, Moro MA, Lorenzo P, Leza JC. Peroxisome proliferator-Activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry. 2005;57:885-894.
31. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta. 2007;1771:1031-1045.
32. Feinstein DL. Therapeutic potential of peroxisome proliferator- activated receptor agonists for neurological disease. Diabetes Technol Ther. 2003;5:67-73.
33. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-Activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997;94:4312-4317.
34. First M, Gibbon M, Spitzer RL, Williams JBW, Smith J. Entrevista clínica estructurada para los trastornos del eje-I del DSM-IV. Barcelona, Spain: Masson; 1999.
35. Ulloa RE, Ortiz S, Higuera F, et al. [Interrater reliability of the Spanish version of Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL)]. Actas Esp Psiquiatr. 2006;34: 36-40.
36. Schreiber E, Matthias P, Müller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419.
37. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686-693.
38. Castro-Fornieles J, Parellada M, Gonzalez-Pinto A, et al. The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. Schizophr Res. 2007;91: 226-237.
39. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085-1097.
40. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
41. Alvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-Analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37: 619-630.
42. Micó JA, Rojas-Corrales MO, Gibert-Rahola J, et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry. 2011;11:26.
43. Arango C, Rapado-Castro M, Reig S, et al. Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry. 2012;69:16-26.
44. Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, Bechdolf A, Schimmelmann BG, Klosterkötter J. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des. 2012;18:351-357.
45. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705-4708.
46. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun. 1997;237:28-32.
47. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry. 2009;65:481-488.
48. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun. 1995;212: 375-380.
49. Yokota O, Terada S, Ishihara T, et al. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:715-721.
50. Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull. 2004;30:923-934.
51. Ghosh N, Ghosh R, Mandal SC. Antioxidant protection: A promising therapeutic intervention in neurodegenerative disease. Free Radic Res. 2011;45:888-905.
52. Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis. 1994;105:165-170.
53. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64:31-39.
54. Dietrich-Muszalska A, Malinowska J, Olas B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res. 2012;37:1057-1062.
55. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-Activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270: 12953-12956.
56. García-Bueno B, Caso JR, Pérez-Nievas BG, Lorenzo P, Leza JC. Effects of peroxisome proliferator-Activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology. 2007;32: 1251-1260.
57. McIntyre RS, Soczynska JK, Lewis GF, MacQueen GM, Konarski JZ, Kennedy SH. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother. 2006;7:1305-1321.
58. Ono N, Abiru T, Sugiyama K, Kamiya H. Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostaglandins Leukot Essent Fatty Acids. 1992;46:59-63.
59. Condray R, Yao JK. Cognition, dopamine and bioactive lipids in schizophrenia. Front Biosci (Schol Ed). 2011;3:298-330.
60. Adkins DE, Khachane AN, McClay JL, et al. SNP-based analysis of neuroactive ligand-receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: data from the CATIE study. Schizophr Res. 2012;135:200-201.